Introduction

There are various radioprotective agents with different mechanisms that help to decrease ionizing radiation side effects. The radioprotective effect of Cimetidine and IMOD was assessed individually and compared with the hybrid radioprotectors agents (HRPAs-IMOD and Cimetidine) on human lymphocyte cells.

Methods

Twenty healthy volunteers (ten men and ten women) participated in the present study. About 75 mL peripheral blood lymphocytes from each individual were collected, and they were divided into 36 groups. Briefly, the blood samples were treated with different concentrations of Cimetidine (12.6 and 25.2 μg/mL) and IMOD (0.04, 0.08, and 0.12 mg/mL), and also a combination of these agents, namely hybrid radioprotectors agents (HRPAs). Besides, the irradiated groups were exposed to 2 and 4 Gy of Co-60 gamma irradiation. The amount of cellular damage was assessed using the micronucleus assay. The repeated measurements and paired T-test statistical analysis were used to compare the micronucleus frequencies in different groups.

Results

The micronucleus frequencies were significantly reduced (p < 0.05) in irradiated groups when the non-toxic concentrations of Cimetidine, IMOD, and HRPAs have been used. The reduction in micronucleus frequency was obtained 5–29% for Cimetidine and 40–51% for IMOD in peripheral blood lymphocytes irradiated with 2 Gy. This reduction in 4 Gy irradiation was 8–17% for Cimetidine and 27–37% for IMOD. The HRPAs resulted in a higher radioprotective effect, in a way that they cause up to 58% and 43% micronucleus frequency reduction in 2 and 4 Gy, respectively.

Conclusion

In conclusion, the HRPAs showed the highest level of radioprotective. In addition, IMOD was remarkably higher radioprotective than Cimetidine, which may be related to its greater non-toxic concentrations.

中文翻译：

---

评估西咪替丁、IMOD 和混合辐射防护剂的辐射防护效果：一项体外研究

介绍

有多种具有不同机制的辐射防护剂有助于减少电离辐射的副作用。单独评估西咪替丁和 IMOD 的辐射防护效果，并与混合辐射防护剂（HRPAs-IMOD 和西咪替丁）对人淋巴细胞的辐射防护效果进行比较。

方法

二十名健康志愿者（十名男性和十名女性）参加了本研究。采集每人约75 mL外周血淋巴细胞，分为36组。简而言之，用不同浓度的西咪替丁（12.6 和 25.2 μg/mL）和 IMOD（0.04、0.08 和 0.12 mg/mL）以及这些药剂的组合，即混合辐射防护剂 (HRPA) 处理血样。此外，照射组分别受到2和4 Gy的Co-60伽马射线照射。使用微核测定评估细胞损伤的量。重复测量和配对T检验统计分析用于比较不同组的微核频率。

结果

当使用无毒浓度的西咪替丁、IMOD 和 HRPA 时，辐照组的微核频率显着降低 (p < 0.05)。在用 2 Gy 照射的外周血淋巴细胞中，西咪替丁的微核频率降低了 5-29%，而 IMOD 降低了 40-51%。西咪替丁的 4 Gy 照射减少了 8-17%，IMOD 减少了 27-37%。HRPA 具有更高的辐射防护效果，它们在 2 Gy 和 4 Gy 中分别导致高达 58% 和 43% 的微核频率降低。

结论

总之，HRPA 显示出最高水平的辐射防护。此外，IMOD 的辐射防护性明显高于西咪替丁，这可能与其更高的无毒浓度有关。